http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Liliana Ulianov (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Safety and Reactogenicity of the Inactivated Poliomyelitis Vaccine (PoliorixTM) in Korea (2006-2012)
신종범,박문성,마상혁,최영륜,신손문,김원덕,Sherine Kuriyakose,Liliana Ulianov,Karin Hardt 대한소아감염학회 2013 Pediatric Infection and Vaccine Vol.20 No.3
Objective: As per the requirement of Korean Food and Drug Administration, this post-marketing surveillance was conducted in Korea to evaluate the safety and reactogenicity of PoliorixTM following its introduction in 2006. Methods: In this open, multicenter study, the vaccine was administered as per the current practice of Korean doctors and in reference to the guidebook by the Korean Pediatric Society and as indicated in the Korean label which was as follows - for primary vaccination three doses were given to infants at ages 2, 4 and 6 months whereas, for the booster dose a single dose was given to children aged 4-6 years. Safety data during this six year surveillance was collected using diary cards which were distributed to the parents to record adverse events. Results: A total of 639 subjects were enrolled into the study. Of these, 617 subjects and 22 subjects received the vaccine as a primary and booster dose, respectively. At least one unsolicited symptom was reported in 11.4% (73/639) of the subjects during the 7-day follow-up period; upper respiratory tract infection (2.5%;16/639) was the most frequently reported unsolicited symptom. One subject reported at least one unsolicited symptom (gastroenteritis) of grade 3 intensity within the 31- day post-vaccination period. Approximately 1.7% (11/639) of subjects reported 13 serious adverse events (SAEs). All SAEs were resolved by the end of the study. Conclusion: In Korea, primary and booster vaccination with PoliorixTM was well-tolerated in healthy subjects when administered according to the prescribing information as part of routine clinical practice.
-
우리나라 영아에서 주사용 소아마비 백신(Poliorix<sup>TM</sup>)의 안전성 및 이상반응에 대한 연구
Sin, Jong Beom,Park, Moon Sung,Ma, Sang Hyuk,Choi, Young Youn,Shin, Son Moon,Kim, Won Duck,Kuriyakose, Sherine,Ulianov, Liliana,Hardt, Karin The Korean Society of Pediatric Infectious Disease 2013 Pediatric Infection and Vaccine Vol.20 No.3
목적: 한국은 2000년에 소아마비 무발생국가로 공인되었으며, WHO의 권고에 의해 2005년부터는 경구용소아마비 생백신 대신 주사용 사백신을 사용하기 시작했다. 본 연구는 2006년부터 국내에서 사용되기 시작한 주사용 소아마비 백신(Poliorix$^{TM}$)의 안전성 및 이상반응을 우리나라 영아들을 대상으로 알아보고자 한다. 방법: 2006년부터 2012년까지 6년 동안 다기관공동연구로 조사하였으며, 2, 4, 6개월의 기초접종과 4-6세의 추가 접종 후 7일 이내 및 31일 이내의 이상반응 및 안전성에 대해 조사하였다. 결과: 총 639명 중 등록대상자 중 617명은 기초접종, 22명은 추가접종을 실시하였으며, 639명 중 73명(11.4%)에서 명시되지 않은 이상반응을 보고하였으며, 이중 가장 많은 증상은 상기도 감염증상으로 접종 후 7일 이내에 639명 중 16명(2.5%)에서 보고되었다. 1명에서 grade 3 이상의 장염증상을 보고하였으며, 11명(1.7%)에서 중대한 이상반응을 보고하였으나, 이들은 모두 연구 종료 이전에 호전되었다. 결론: 6년 동안의 시판 후 조사에서, 건강한 우리나라 영아들을 대상으로 한 주사용 소아마비 사백신(Poliorix$^{TM}$) 접종은 국내 건강한 소아에서 안전하고 내약성이 충분하였다. Objective: As per the requirement of Korean Food and Drug Administration, this post-marketing surveillance was conducted in Korea to evaluate the safety and reactogenicity of Poliorix$^{TM}$ following its introduction in 2006. Methods: In this open, multicenter study, the vaccine was administered as per the current practice of Korean doctors and in reference to the guidebook by the Korean Pediatric Society and as indicated in the Korean label which was as follows - for primary vaccination three doses were given to infants at ages 2, 4 and 6 months whereas, for the booster dose a single dose was given to children aged 4-6 years. Safety data during this six year surveillance was collected using diary cards which were distributed to the parents to record adverse events. Results: A total of 639 subjects were enrolled into the study. Of these, 617 subjects and 22 subjects received the vaccine as a primary and booster dose, respectively. At least one unsolicited symptom was reported in 11.4% (73/639) of the subjects during the 7-day follow-up period; upper respiratory tract infection (2.5%;16/639) was the most frequently reported unsolicited symptom. One subject reported at least one unsolicited symptom (gastroenteritis) of grade 3 intensity within the 31-day post-vaccination period. Approximately 1.7% (11/639) of subjects reported 13 serious adverse events (SAEs). All SAEs were resolved by the end of the study. Conclusion: In Korea, primary and booster vaccination with Poliorix$^{TM}$ was well-tolerated in healthy subjects when administered according to the prescribing information as part of routine clinical practice.
KCI
KISS연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
